argenx - ARGX-117 revealing more of its treatment potential
Interim analysis based on the 1st dose cohort in the Ph2 ARDA study indicates favorable safety and initial signs of efficacy.The company will now initiate treatment of the 2nd dose cohort and we expect more data details in '24. No impact on investment case and valuation since we do not yet take into account estimates related to this program. Buy rating and TP reiterated. We expect more news regarding the regulatory approval of subcu Efgar for gMG later today.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.